Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), filed a Form 4 on October 29, 2026, disclosing two sales of common stock on October 27 and October 28, 2026, executed under Rule 10b5-1 plans to cover tax withholding obligations related to vesting restricted stock units.

Key Highlights

  • First sale: 1,010 shares of common stock disposed of on October 27, 2026, at $406 per share.
  • Second sale: 1,162 shares of common stock disposed of on October 28, 2026, at $426.3404 per share.
  • Total shares sold: 2,172 shares across both transactions, both coded as dispositions (S).
  • Remaining ownership: 104,742 shares of common stock held directly following the reported transactions.
  • Purpose: Both sales were made to satisfy tax withholding and remittance obligations connected to RSU vesting events.
  • Rule 10b5-1 plans: The October 27 sale was pursuant to a Stock Unit Agreement granted January 26, 2024; the October 28 sale was pursuant to Stock Unit Agreements granted January 27, 2023.

Natera President Solomon Moshkevich Discloses RSU-Related Share Sales in Late October 2026

According to the Form 4 filing, Solomon Moshkevich, who serves as President of Clinical Diagnostics at Natera, Inc., disposed of a combined 2,172 shares of common stock over two consecutive trading days. On October 27, 2026, he sold 1,010 shares at $406 per share. On October 28, 2026, he sold 1,162 shares at $426.3404 per share. Both transactions are coded "S" (open-market or planned sale) and are listed as direct ownership dispositions.

The filing attributes both sales to tax withholding and remittance obligations arising from the vesting of restricted stock units. The filing states that the October 27 transaction "was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024." Similarly, the October 28 sale was made under Rule 10b5-1(c) pursuant to Stock Unit Agreements granted on January 27, 2023.

Following both transactions, Moshkevich directly held 104,742 shares of Natera common stock, according to the filing. No derivative securities were reported in Table II of the form. The filing was signed by Tami Chen as Attorney-in-Fact on October 29, 2026.

What Was Disclosed

Solomon Moshkevich, President of Clinical Diagnostics at Natera, disclosed the sale of 2,172 total shares of common stock on October 27-28, 2026, at prices of $406 and $426.3404 per share, both executed under Rule 10b5-1 plans to meet RSU tax withholding obligations.